United States Gastrointestinal Therapeutics Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Takeda, Novartis, Pfizer, Merck, F. Hoffmann-La Roche, Eli Lilly, AstraZeneca

Gastrointestinal Therapeutics Market is estimated to grow at a CAGR of 6.42% during the forecast period 2024-2031.

DataM Intelligence has published a new research report on "Gastrointestinal Therapeutics Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/gastrointestinal-therapeutics-market?sg

Key Players: Abbott, Allergan, Johnson & Johnson, Takeda, Novartis, Pfizer, Merck, F. Hoffmann-La Roche, Eli Lilly, AstraZeneca, Procter & Gamble, and Shire Pharmaceuticals.

USA - Industry Latest News 2025:

✅ 24 Feb 2025 - Biocon Biologics launches YESINTEKTM (ustekinumab-kfce) in the United States (biosimilar to Stelara) - indicated for Crohn's disease and ulcerative colitis (and psoriasis/PsA).

✅ 19 Mar 2025 - FDA grants traditional approval to pembrolizumab (KEYTRUDA) + trastuzumab + chemotherapy as 1L treatment for HER2-positive gastric / gastroesophageal junction adenocarcinoma (PD-L1 CPS≥1).

✅ 13 Jan 2025 - GSK enters agreement to acquire IDRx (US clinical-stage company) - includes IDRX-42, a KIT TKI targeting gastrointestinal stromal tumours (GIST); deal up to ~$1.15B (adds to GI-cancer pipeline).

Japan - Industry Latest News 2025:

✅ 07 Jan 2025 - PMDA approves Biocon Biologics' ustekinumab biosimilar (Bmab-1200 / Yesintek®) for the Japanese market.

✅ 21 May 2025 - Yoshindo (Biocon's partner) launches the subcutaneous ustekinumab biosimilar in Japan (commercial rollout following PMDA approval).

✅ 2025 (ongoing) - PMDA / Japan regulatory updates & activity supporting faster access (PMDA updates and approvals continue through 2025), with Japan remaining active on IBD/biologic approvals.

Korea (South Korea) - Industry Latest News 2025:

✅ Apr 2025 - "2025 Seoul Consensus" (Korean Society of Neurogastroenterology & Motility) - updated clinical practice guidelines for functional GI disorders (IBS/constipation/GERD updates published in 2025).

✅ Mar-Jun 2025 - MFDS (Korean Ministry of Food & Drug Safety) regulatory activity: MFDS programs to bolster innovative product development and revised GMP/regulatory guidance (regulatory support measures rolled out in 2025).

Europe - Industry Latest News 2025:

✅ 18 Feb 2025 - European Commission grants marketing authorisation for Biocon Biologics' YESINTEK® (ustekinumab biosimilar) - indication includes Crohn's disease.

✅ 25 Apr 2025 - European Commission approves TREMFYA® (guselkumab) for adults with moderately-to-severely active ulcerative colitis (Johnson & Johnson) - new IBD approval in EU 2025.

✅ 17-18 Sep 2025 (deal announced Sept 17-18, 2025) - Roche signs definitive agreement to acquire US biotech 89bio (adds pegozafermin, an FGF21 analogue in development for MASH / fatty-liver disease).

Growth Forecast Projected:
The Global Gastrointestinal Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Gastrointestinal Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Purchase this report before year-end and unlock an exclusive 30% discount: - https://www.datamintelligence.com/buy-now-page?report=gastrointestinal-therapeutics-market?sg

(Purchase 2 or more Repots and get 50% Discount)

Key Segments:

By Product Category (Branded, Generic)

By Route of Administration (Oral, Parenteral, Others)

By Application (Ulcerative Colitis, GI Bleeding, Laxatives, Irritable Bowel Syndrome, Peptic Ulcer Disease (PUD), Others),

By End User (Hospitals, Clinics, Others)

By Distribution Channel (Hospital Pharmacie, Retail Pharmacies, Online Pharmacies)

By Region (North America, South America, Europe, Asia Pacific, Middle East & Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Gastrointestinal Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Gastrointestinal Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/gastrointestinal-therapeutics-market?sg

FAQ's

Q1: How fast is the Gastrointestinal Therapeutics Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 6.42% from 2024-2031

Q2: Which regions are dominating the Gastrointestinal Therapeutics Market and which are fastest-growing?

A: North America region holds the largest market share of the global Gastrointestinal Therapeutics market.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/gastrointestinal-therapeutics-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?sg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.